TELMISIGN AM Tablet is a fixed-dose combination medication that combines two potent antihypertensive agents: Telmisartan, an angiotensin II receptor blocker (ARB), and Amlodipine, a calcium channel blocker (CCB). This synergistic formulation is designed for patients requiring dual therapy to achieve optimal blood pressure control when monotherapy is insufficient.
Telmisartan works by blocking the angiotensin II receptor, thereby preventing vasoconstriction and promoting vasodilation, which reduces systemic vascular resistance and lowers blood pressure. Amlodipine complements this action by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle, further aiding in vessel relaxation and improved circulation.
TELMISIGN AM is indicated for the management of essential hypertension, especially in patients who benefit from both ARB and CCB action. The once-daily dosing enhances patient adherence, while the dual mechanism of action ensures comprehensive blood pressure control throughout the day and night.
Manufactured under strict GMP compliance by Bluepill Express, TELMISIGN AM undergoes rigorous quality checks, including assay, dissolution, microbial testing, and stability analysis. It is available in standard packaging formats that ensure shelf-life stability and product integrity.
This combination is particularly beneficial for hypertensive patients at risk of cardiovascular events, left ventricular hypertrophy, or chronic kidney disease. TELMISIGN AM is generally well tolerated, though some patients may experience side effects such as dizziness, ankle swelling, or fatigue. It is contraindicated in pregnancy and should be used with caution in patients with severe hepatic or renal impairment.
Description provided by bluepill express.
FIEO Registered
Export Ready
